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Introduction
In the United States and Western Europe, approximately 5% of 
breast cancer (BC) patients present with stage IV at their primary 
diagnosis [1]. Stage IV BC is defined as BC that has metastasized to 
distant organs. The standard therapeutic approach is palliative; 
systemic therapy is considered the mainstay of treatment [2, 3]. 
Local resection of the primary tumor is recommended for symp-
tom control, e.g. for ulceration and bleeding or alleviation of pain. 
A substantial survival benefit due to resection of the primary tumor 
is not expected for stage IV BC. The development of new systemic 
therapy regimens and new agents has led to a significant increase 
in the overall survival (OS) of patients suffering from metastatic 
disease [4]. With this gain in survival time, the risk of local pro-
gression and associated problems also increases, which justifies 
considering local resection as part of the initial treatment 
approach.
Additionally, several retrospective studies reported an associa-
tion of local resection with increased survival time [5, 6].
It has been assumed that a decrease of circulating tumor cells 
(CTCs) by surgical reduction of the total tumor volume (including 
tumor stem cells as a source of CTCs) decreases the rate of new 
metastasis and is therefore associated with a better prognosis [7]. 
Another reason for longer survival after resection of the pri-
mary tumor might be an activation of autoimmunity and an in-
crease in drug efficacy [8].
With the availability of more sensitive imaging modalities such 
as positron emission tomography/computed tomography (PET/
CT), the profile of metastatic breast cancer (MBC) has changed. 
Patients with metastatic disease can be diagnosed earlier, which 
confronts us with a new group of patients with ‘low tumor burden’. 
These patients might be good candidates for local resection. 
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Summary
Background: This study aimed to identify the association 
of local surgery of the primary tumor in metastatic breast 
cancer (MBC) patients with overall survival (OS) and 
prognostic factors. Patients and Methods: Patients with 
primary MBC (1990–2006) were included in our retrospec-
tive analysis (n = 236). 83.1% had surgery for the primary 
tumor. OS was evaluated using Kaplan-Meier estimates. 
Predictive factors for OS were determined. Results: Me-
dian follow-up was 123 months for all patients still alive 
at the time of analysis. In univariate analysis, patients 
with surgery of the primary tumor had significantly pro-
longed OS (28.9 vs. 23.9 months). Within the surgery 
group, patients with MBC limited to 1 organ system had a 
better outcome (39.3 vs. 24.9 months), as did asympto-
matic patients. Independent risk factors for shorter OS 
were hormone receptor negativity, symptoms, and in-
volvement of  1 organ system. Conclusion: Patient se-
lection for local therapy was confounded by a more fa-
vorable profile and a lesser tumor burden before surgery, 
which might implicate a bias. Nevertheless, our univari-
ate results indicate that local surgery of the primary 
tumor in MBC patients could be considered as part of the 
therapeutic regimen in selected patients. However, larger 
patient numbers are needed to prove these findings in 
the multivariate model. 
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To our knowledge, up to now, final results from only 2 prospec-
tive studies are available focusing on the question whether local 
therapy of the primary tumor in stage IV BC has an effect on the 
prognosis and survival of such patients [9, 10]. A number of prom-
ising randomized trials investigating this topic are underway (still 
recruiting or in follow-up), summarized by Shien [11].
The purpose of our study was to identify the potential impact of 
surgical therapy of the primary tumor in patients with primary 
stage IV BC. 
Patients and Methods
Between 1990 and 2006, 236 patients with primary MBC treated at the Uni-
versity Hospital Munich Grosshadern were included in this retrospective analy-
sis. 16.9% of these patients had received no local surgical treatment, whereas 
83.1% had undergone surgery. Exclusion criteria from our analysis were as fol-
lows: radiation as the only local treatment, no systemic treatment, non-resecta-
ble primary tumors, and death within 30 days of presentation. Patient demo-
graphics are presented in table 1.
Patients in the non-surgery group were significantly more likely to have me-
tastases to multiple organ systems (57.5 vs. 33.7%) and involvement of the central 
nervous system (CNS) (7.5 vs. 3.1%) (p < 0.001). Patients without surgery pre-
sented significantly more frequently with symptoms (82.5 vs. 52.0%) (p < 0.001).
Most patients who underwent surgery received systemic therapy after sur-
gery (139/196, 70.9%). The remaining patients (57/196, 29.1%) were treated 
with primary systemic therapy (chemo or endocrine therapy) followed by sur-
gery within 3–6 month of the tumor being diagnosed.
Starting with the official approval of trastuzumab for MBC in Germany in 
2000, most patients received trastuzumab if treated with chemotherapy (n = 
10; no surgery: n = 2, surgery: n = 8). Trastuzumab was not used in patients 
with endocrine first-line treatment or anthracycline-based first-line chemo-
therapy.
Kaplan-Meier estimates were used to evaluate OS which was specified as the 
time interval from primary diagnosis of MBC to death from any cause. The 
 log-rank test was used to assess survival differences between groups in the uni-
variate analysis. 
Multivariate Cox proportional hazards regression models were used to 
identify potential prognostic factors associated with survival.
A test for interaction was performed for an exploratory subgroup analysis of 
the differential effect of surgery on prognosis.
All analyses were carried out with SPSS software (IBM SPSS Version 22; 
IBM Corp., Armonk, NY, USA). All tests were two-sided using a significance 
level of 0.05.
Results
Median follow-up after the primary diagnosis was 27 (1–218) 
months (median follow-up for all patients still alive at the time of 
analysis was 123 (27–180) months). At the time of analysis, the ob-
served mortality was 87.2% (206/236 patients), 17 patients were 
lost to follow-up, and 13 patients were still alive.
Table 1. Patient demographics





Age, median  
(range), years
57 (33–93)  58 (28–86) ns  58 (28–93)
Patients, n (%) 40 (16.9) 196 (83.1) 236 (100.0)
T stage, n (%)
T1–3 23 (57.5) 129 (65.8) ns 152 (64.4)
T4 17 (42.5)  67 (34.2)  84 (35.6)
Grade, n (%)
G1 and G2 30 (75.0)  88 (44.9) 0.001 118 (50.0)
G3 10 (25.0) 108 (55.1) 118 (50.0)
HR status, n (%)
Positive 33 (82.5) 146 (74.5) ns 179 (75.8)
Negative  7 (17.5)  50 (25.5)  57 (24.2)
HER2 status, n (%)
Positive  4 (10.0)  25 (12.8) ns  29 (12.3)
Negative 21 (52.5)  89 (45.4) 110 (46.6)
Missing 15 (37.5)  82 (41.8)  97 (41.1)
Organ systems involved, n (%)
1 14 (35.0) 125 (63.8) <0.001 139 (58.9)
2 10 (25.0)  44 (22.4)  54 (22.9)
3 10 (25.0)  22 (11.2)  32 (13.6)
> 3  6 (15.0)   5 (2.6)  11 (4.7)
Location of metastasis, n (%)
Bone only  8 (20.0)  84 (42.9) 0.009  92 (39.0)
Sing. visc./soft  6 (15.0)  40 (20.4)  46 (19.5)
Multiple 23 (57.5)  66 (33.7)  89 (37.7)
+CNS  3 (7.5)   6 (3.1)   9 (3.8)
Symptoms, n (%)
No  7 (17.5)  94 (48.0) <0.001 101 (42.8)
Yes 33 (82.5) 102 (52.0) 135 (57.2)
First-line systemic treatment, n (%)
Chemotherapy 18 (45.0) 109 (55.6) ns 127 (53.8)
Endocrine 22 (55.0)  87 (44.4) 109 (46.2)
Lost to follow-up,  
n (%)
 6 (15.0)  11 (5.6) 0.03  17 (7.2)
HR = Hormone receptor; Sing. visc./soft = single visceral organ/soft tissue  
( 1 organ); multiple = ≥ 2 organs; +CNS = CNS involvement ± other;  
ns = not significant.
Fig. 1. Overall survival (OS) in relation to local surgery in M1 patients (no 
local surgery vs. local surgery): median OS (95% confidence interval) 23.9 
(19.3–28.5) vs. 28.9 (22.2–35.7) months; p = 0.015. 
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Fig. 2. Number of metastases and overall survival (OS) in relation to local surgery (no local surgery vs. local surgery. A M1 patients with metastases limited to 1 organ 
system: median OS (95% confidence interval (CI)) 24.9 (16.3–33.6) vs. 39.3 (31.4–47.3) months; p = 0.012. B M1 patients with metastases limited to 2 organ systems: 
median OS (95% CI) 39.2 (23.2–55.2) vs. 16.3 (10.3–22.4) months; not significant (ns). C M1 patients with metastases limited to 3 organ systems: median OS (95% CI) 
15.0 (7.2–38.0) vs. 22.1 (13.9–30.3) months; ns. D M1 patients with metastases to > 3 organ system: median OS (95% CI) 2.8 (0.0–22.5) vs. 9.8 (0.5–19.2) months; ns.
In the univariate model, patients with surgical therapy of the 
primary breast tumor had significantly prolonged median OS of 
28.9 (22.2–35.7) vs. 23.9 (19.3–28.5) months (p = 0.015) (fig. 1).
The association of local treatment with OS compared to no local 
surgery was not homogenous across all subgroups. In more advanced 
disease groups, local treatment was not associated with a significant 
OS prolongation. Local surgery did not show any significant effect on 
survival outcome in patients with involvement of 2 organ systems 
(16.3 (10.3–22.4) vs. 39.2 (23.2–55.2) months; not significant), 3 
organ systems (22.1 (13.9–30.3) vs. 15.0 (7.2–38.0) months; not sig-
nificant), and more than 3 organ systems (9.8 (0.5–19.2) vs. 2.8 (0.0–
22.5) months; not significant). However, patients with MBC limited 
to 1 organ system had significant prolongation of OS after local sur-
gery (39.3 (31.4–47.3) vs. 24.9 (16.3–33.6) months; p = 0.012) (fig. 2). 
Patients with metastatic disease limited to 1 visceral organ or 1 
soft tissue system, presented with prolonged OS in the surgery 
group (27.3 (17.4–37.2) vs. 13.4 (0–29.8) months; p = 0.042). A 
considerable prolongation of OS was also observed in patients with 
bone metastases only (43.3 (33.3–53.3) vs. 24.9 (16.6–33.3) months; 
p = 0.115) (fig. 3). 
Patients with metastases to multiple organ systems (19.0 (10.6–
27.4) vs. 25.9 (14.1–37.7) months; not significant) or any CNS in-
volvement (2.1 (0–6.5) vs. 2.8 (2.7–2.8) months; not significant) 
had no significant improvement in survival after surgery (fig. 3).
Patients who were asymptomatic at presentation had a signifi-
cantly higher increase in OS after surgery (37.5 (23.8–51.2) vs. 15.0 
(11.5–18.6) months; p = 0.029) compared to symptomatic patients 
(24.7 (17.3–32.2) vs. 23.9 (19.3–28.5) months; not significant). 
In the multivariate analysis, patients with hormone receptor-
negative BC were significantly more likely to have shorter survival 
(relative risk (RR) 1.6; p = 0.004). The RR of dying increased with 
an increasing number of involved organ systems (p < 0.001). The 
risk for shorter survival was significantly higher in patients pre-




The exploratory analysis of particular groups revealed surgery 
not to be associated with a homogenous effect on survival across 
the subgroups. In general, cases with a lower tumor load (e.g. less 
involved organ systems or asymptomatic disease) had a higher 
Fig. 3. Location of metastases and overall survival (OS) in relation to local surgery (no local surgery vs. local surgery). A M1 patients with metastases  limited to 
the bone: median OS (95% confidence interval (CI)) 24.9 (16.6–33.3) vs. 43.3 (33.3–53.3) months; p = 0.115. B M1 patients with singular metastases to visceral or 
soft tissue only (1 organ system only): median OS (95% CI) 13.4 (0–29.8) vs. 27.3 (17.4–37.2) months; p = 0.042. C M1 patients with metastases to multiple organ 
systems: median OS (95% CI) 25.9 (14.1–37.7) vs. 19.0 (10.6–27.4); not significant (ns). D M1 patients with central nervous system involvement: median OS (95% 
CI) 2.8 (2.7–2.8) vs. 2.1 (0–6.5) months; ns.
RR (95% CI) p
HR negative vs. positive 1.6 (1.2–2.2) 0.004
2 organs vs. 1 organ involved 1.5 (1.1–2.2) 0.013
3 organs vs. 1 organ involved 2.0 (1.3–3.0) 0.002
> 3 organs vs. 1 organ involved 3.3 (1.8–6.3) <0.001
Symptomatic vs. asymptomatic disease 1.7 (1.3–2.3) <0.001
Covariables included in the Cox regression model: tumor stage, grade, HR status, number of involved 
 organs, type of metastases, symptoms, local treatment, menopausal status, type of systemic treatment 
(non-significant results not shown: tumor stage, grade, type of metastases, local treatment, menopausal 
status, type of systemic treatment).
RR = Relative risk; CI = confidence interval; HR = hormone receptor.
Table 2. Multivariate analysis 
benefit from surgery. The test for interaction was significant for 
number of involved organ systems, location, and symptoms (fig. 4).
A landmark analysis limiting the presented data to only patients 
who survived for more than 6 months revealed similar results. Pa-
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tients with bone metastasis only, metastases limited to 1 organ sys-
tem, or asymptomatic disease had a considerably better prognosis 
in the surgery group, whereas all other groups showed no associa-
tion with an effect of surgery (data not shown).
Discussion
In the univariate analysis, those patients with metastatic disease 
who had the primary tumor surgically removed showed signifi-
cantly improved OS, which is consistent with other studies [5, 6, 
12].
Different hypotheses exist to explain this positive effect of local 
surgery in the advanced stage of the disease. However, the true 
mechanism remains unclear. Removal of the primary tumor and 
thereby reduction in the total tumor burden is supposed to be as-
sociated with reduced tumor-induced immunosuppression [8] 
and decreased self-seeding of the primary tumor to distant sites 
[13], which again could be due to a reduction in CTCs [14]. Asso-
ciated removal of BC stem cells, which can be the source of 
chemo-resistant clones, could influence outcome in a positive way 
by making metastases more sensitive to chemotherapeutic regi-
mens [15]. 
The benefit of local surgery in MBC patients is not supported by 
results of a prospective randomized controlled trial conducted in 
India with 350 patients. This cohort received initial treatment with 
6 cycles of anthracycline-based chemotherapy or endocrine ther-
apy, and only patients who responded well to chemotherapy were 
enrolled in the study. Surgery did not extend survival in this trial. 
After 2 years, 41.9% of those who underwent breast surgery fol-
lowed by radiotherapy were alive compared to 43.0% of women 
who received no local therapy [9]. The exclusion of non-respond-
ers to chemotherapy is in contrast to our study which did not ex-
clude patients with a poor prognosis or low response to systemic 
treatment. 
The prospective Indian trial focused on patients with a higher 
risk profile, while in our retrospective study the number of patients 
with low-risk metastases was substantially higher.
Consistent with the Indian randomized trial, we were unable to 
observe any substantial benefit from surgery in patients with high-
risk metastases (limiting the analysis to patients who did not sur-
vive the first 6 months after diagnosis). Focusing on the low-risk 
patients, however, we could see a survival benefit in the surgery 
group in all univariate-analyzed subgroups (in patients with a doc-
umented survival of more than 6 months). However, in our multi-
variate model, no effect of local surgery was seen.
Fig. 4. Exploratory subgroup analysis. RR< 1  surgery favorable, RR > 1  surgery unfavorable (RR = Relative risk; CI = confidence interval; interaction = test of 





Regarding the inclusion criteria for patients, our study is more 
comparable to another prospective randomized study conducted in 
Turkey [10]. In this study, the survival rate after 40 months of me-
dian follow-up was significantly higher in the surgery group (46 vs. 
37 months). The treatment algorithm differed between the 2 pro-
spective studies. In contrast to the Indian study, all the Turkish 
women assigned to locoregional therapy received systemic therapy 
after breast-conserving surgery and breast irradiation – not before. 
Furthermore, patients with HER2-positive tumors were treated 
with trastuzumab.
In our analysis, the majority of patients who were treated surgi-
cally received systemic therapy after the surgery (71%). Pre- or 
postoperative systemic treatment did not result in significantly dif-
ferent outcome.
Besides the survival benefit found in the total cohort after local 
surgery, the Turkish investigators, similar to us, also identified sub-
groups who had a significant benefit from local surgery, i.e. pa-
tients with less aggressive tumor biology and patients with metasta-
ses limited solely to the bone [10].
This is strikingly similar to our univariate findings. We also ob-
served a significant prolongation of survival in patients with dis-
ease limited to the bone in the surgery group. 
In a review focusing on surgery in metastatic patients, Hart-
mann et al. [16] state that based on current data, locoregional treat-
ment in primary MBC should not be routinely recommended in 
patients with asymptomatic primary tumors. In contrast, our data 
suggest that survival was longer especially in asymptomatic pa-
tients of the surgery group. 
Patients with involvement of only 1 organ system were treated 
more often with surgery of the primary tumor, which is consistent 
with the findings of a meta-analysis of 10 studies including almost 
29,000 patients with MBC [17].
Yet, in our analysis, the decision for local treatment was biased by 
the extent and presentation of the metastatic disease. Patients with 
more advanced MBC seemed to not benefit from removal of the pri-
mary tumor. A reason for this could be that a reduction in total 
tumor burden loses its effect once a certain tumor load is reached.
There are some limitations to our analysis: One obvious limita-
tion is the retrospective and monocentric design. The selection of 
patients for local therapy was confounded by a more favorable pro-
file and lesser tumor burden (higher proportion of oligometastatic 
patients, and bone metastases only) before surgery, which might 
implicate a selection bias. 
To address the problem of bias by including patients who died 
early following the primary diagnosis of MBC, we performed a 
landmark analysis limiting the presented data to only patients who 
survived more than 6 months. In doing so, patients were excluded 
in whom poor tumor biology would have dictated the survival end-
points independent of local intervention. The results were almost 
identical.
A possible strength of our analysis is the substantial follow-up 
and patient numbers. However, the latter still seems too small to 
confirm an effect of local surgery in the multivariate model.
A current review supports the potential OS benefit we observed 
in the local surgery group in patients with oligometastatic disease, 
especially if limited to the bone [18]. 
The treatment of MBC will always be a multimodal approach 
influenced by the patient’s age and comorbidities as well as specific 
tumor characteristics.
Despite the enormous problem of bias in a retrospective trial, es-
pecially in the complex situation of MBC, our univariate data were 
similar to those of the 2 randomized trials published so far [9, 19].
According to our analysis, asymptomatic patients and those 
with only 1 involved organ system (especially bone only) could be 
considered low-risk, while patients with symptomatic disease or 
more than 1 involved organ system or CNS metastases should be 
considered high-risk.
Essentially, surgery of the primary tumor should only be offered 
to metastatic high-risk patients if local control seems helpful in the 
context of palliative treatment. In contrast, for patients with low-
risk metastases, surgery could potentially provide a small but sig-
nificant survival benefit and could be offered more liberally.
Patients with oligometastatic disease to the bone and limited 
metastatic disease burden might be potential candidates for local 
surgery in that situation.
However, since local surgery lacked significance in the multi-
variate model, we suggest to investigate this topic with larger pa-
tient numbers.
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